Evidence map›Paper›PMID 39045728›Full record

ArticleLupus2024

A qualitative investigation of the experiences of patients living with antiphospholipid antibodies.

Francesca S Cardwell, Alexandra O Kobza, Susan J Elliott, Paul S Gibson, Nancy Soliman, Leslie Skeith, Ann E Clarke, Megan Rw Barber

Abstract read
In one paragraph

Article in Lupus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francesca S CardwellDepartment of Geography & Environmental Management, University of Waterloo, Waterloo, ON, Canada.ORCID 0000-0002-7393-466X
Alexandra O KobzaDivision of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Susan J ElliottDepartment of Geography & Environmental Management, University of Waterloo, Waterloo, ON, Canada.
Paul S GibsonDepartment of Obstetrics & Gynecology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Nancy SolimanDepartment of Obstetrics & Gynecology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Leslie SkeithDivision of Hematology and Hematological Malignancies, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Ann E ClarkeDivision of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Megan Rw BarberDivision of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSubstantial morbidity and mortality affect those with antiphospholipid antibodies (aPLs) and antiphospholipid syndrome (APS), yet patient experiences remain poorly understood. This research investigated patient experiences of aPL/APS diagnosis; effects on daily life; and healthcare and treatment.

methodsPatients aged ≥18 years with APS per the Revised Sapporo criteria or with ≥1 positive aPL on ≥2 occasions were recruited from a Canadian multidisciplinary APS clinic to participate in semi-structured in-depth interviews. Interviews were conducted virtually and transcribed verbatim for subsequent thematic analysis.

resultsTwenty-one patients with aPLs/APS participated; 95.2% were female, mean (SD) age was 45.6 (15.0) years. Most (71.4%) had APS, and 71.4% had aPLs/APS with SLE. Results are presented around patient experiences of aPL/APS diagnosis, effects on daily life, and healthcare and treatment. Participants described medical complications/physical symptoms and the healthcare, lifestyle, and emotional impacts experienced around the time of aPLs/APS diagnosis. In addition to the physical and psychosocial impacts of living with aPLs/APS, patients reported modified leisure activities, altered employment trajectories, and positive and negative impacts on relationships. Impacts on family planning were also a critical component of the aPL/APS lived experience; participants shared experiences of miscarriage, other pregnancy complications, and medication-related challenges (e.g., with low-molecular-weight heparin injections). Challenging aspects of aPL/APS healthcare and treatment were also discussed, particularly related to the lifestyle, physical, and emotional burden of medication use. Although a lack of resources was described, participants expressed trust in healthcare providers when making management decisions or when seeking information. Suggestions for resources included the need for additional medication-related information, examples to help contextualize management behaviours, and additional information for those with aPLs/APS without SLE.

conclusionPatients highlighted how the diverse manifestations of aPLs/APS, accentuated by management-related challenges, impose considerable physical and psychosocial burdens. Results will inform the development of patient resources aligned with patient priorities.

Indexed as

Antibodies, AntiphospholipidAntiphospholipid SyndromeQualitative ResearchAdultCanadaFemaleHumansInterviews as TopicLife StyleLupus Erythematosus, SystemicMaleMiddle AgedPregnancyQuality of LifeAntibodies, Antiphospholipidantiphospholipid antibodiesantiphospholipid syndromequalitativeSystemic lupus erythematosus

Identifiers

PMID39045728
PMCPMC11977815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.